Bridging disciplines and elevating care: A Q&A with John Gelles, OD, and Steven Greenstein, MD
In this Q&A, John D. Gelles, OD, and Steven Greenstein, MD, chat about what inspired them to launch the symposium, what makes this year’s agenda especially exciting, and why the future of refractive care depends on stronger collaboration between ODs and MDs.
ARVO 2025: Miebo demonstrates favorable tolerability in prescription refill rates
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, details the key takeaways from a poster presentation she participated in during ARVO 2025.
ARVO 2025: The early adoption and utilization of perfluorohexoloctane (Miebo)
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
A sneak peek into the Collaborative Care Symposium 2025 with Steven Greenstein, MD
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
ARVO 2025: Dr Julie Poteet reviews patient-reported outcomes following use of Blink Triple Care
May 23rd 2025The study targets a prevalent yet under-addressed component of dry eye disease: lipid layer dysfunction, implicated in approximately 86% of dry eye cases, especially those associated with screen use and environmental exposure.
Predicting presbyopia reading ADD and progression with AI and machine learning algorithm
Digital Twin and VESA can integrate refractive data, topography, biomechanical properties, and even simulate age-related changes in the eye—turning it into a predictive and diagnostic tool for clinicians managing complex conditions like presbyopia.
ARVO 2025: Rethinking centile growth curves in myopia management with Mark Bullimore, MCOptom, PhD
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
CIME 2025: Luke Lindsell, OD, MD, on bridging innovation and practical care in retinal disease
May 8th 2025Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda Light Delivery System (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.
ARVO 2025: Exploring a conversion factor between 2 OCT devices to monitor glaucoma progression
Hammond and his team focused on creating a reliable conversion factor between 2 widely used optical coherence tomography (OCT) systems—the TopCon Maestro2 and the ZEISS Cirrus 5000. Their work specifically looked at ganglion cell–inner plexiform layer and retinal nerve fiber layer thickness measurements, which are critical markers in glaucoma diagnosis and monitoring.